ARTICLE | Finance

Neo is the time

Why VCs flocked to Andrew Allen's cancer newco Gritstone

October 26, 2015 7:00 AM UTC

With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer from a lack of VC interest for his newest cancer venture. His Gritstone Oncology Inc. launched last week and raised $102 million in the third-largest biotech series A round this year.

Versant Ventures and The Column Group led the round. Other investors included Clarus Ventures, Frazier Healthcare, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity...